 Kathleen Barnes
Concepts (710)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 85 | 2023 | 2158 | 6.260 |
Why?
| | Dermatitis, Atopic | 27 | 2023 | 332 | 5.530 |
Why?
| | Genetic Predisposition to Disease | 76 | 2023 | 2275 | 5.100 |
Why?
| | Polymorphism, Single Nucleotide | 85 | 2023 | 2062 | 4.400 |
Why?
| | Immunoglobulin E | 35 | 2023 | 365 | 3.790 |
Why?
| | Genome-Wide Association Study | 59 | 2023 | 1323 | 3.780 |
Why?
| | Kaposi Varicelliform Eruption | 12 | 2021 | 36 | 2.720 |
Why?
| | Genome, Human | 21 | 2023 | 387 | 2.490 |
Why?
| | Genotype | 43 | 2023 | 1882 | 2.180 |
Why?
| | Hypersensitivity | 12 | 2023 | 268 | 2.020 |
Why?
| | Precision Medicine | 12 | 2024 | 363 | 2.010 |
Why?
| | Linkage Disequilibrium | 21 | 2021 | 273 | 1.790 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 17 | 2021 | 1137 | 1.750 |
Why?
| | Polymorphism, Genetic | 12 | 2017 | 642 | 1.590 |
Why?
| | Helminthiasis | 3 | 2017 | 13 | 1.480 |
Why?
| | Gene Frequency | 22 | 2022 | 513 | 1.440 |
Why?
| | Genetic Variation | 17 | 2022 | 926 | 1.400 |
Why?
| | Genetic Loci | 15 | 2022 | 281 | 1.400 |
Why?
| | Alleles | 22 | 2023 | 832 | 1.290 |
Why?
| | Sepsis | 7 | 2023 | 531 | 1.260 |
Why?
| | Whole Genome Sequencing | 10 | 2021 | 113 | 1.240 |
Why?
| | Biological Specimen Banks | 6 | 2024 | 104 | 1.170 |
Why?
| | Humans | 216 | 2024 | 118972 | 1.130 |
Why?
| | Genetic Linkage | 17 | 2012 | 321 | 1.110 |
Why?
| | Hypersensitivity, Immediate | 10 | 2011 | 59 | 1.080 |
Why?
| | Genetics, Population | 12 | 2021 | 207 | 1.080 |
Why?
| | Chromosome Mapping | 16 | 2018 | 510 | 1.040 |
Why?
| | Case-Control Studies | 30 | 2020 | 3171 | 0.960 |
Why?
| | Gene Expression Profiling | 15 | 2017 | 1597 | 0.940 |
Why?
| | Pharmacogenetics | 3 | 2020 | 151 | 0.930 |
Why?
| | HLA-DQ beta-Chains | 2 | 2021 | 61 | 0.920 |
Why?
| | Chromosomes, Human, Pair 11 | 8 | 2014 | 66 | 0.900 |
Why?
| | Haplotypes | 18 | 2021 | 473 | 0.870 |
Why?
| | Genetic Association Studies | 9 | 2021 | 371 | 0.870 |
Why?
| | Phenotype | 32 | 2023 | 3003 | 0.850 |
Why?
| | Male | 119 | 2022 | 57801 | 0.820 |
Why?
| | Interleukin-4 | 4 | 2023 | 215 | 0.820 |
Why?
| | HLA-A2 Antigen | 1 | 2021 | 39 | 0.820 |
Why?
| | Female | 119 | 2022 | 61564 | 0.800 |
Why?
| | Barbados | 13 | 2013 | 23 | 0.790 |
Why?
| | Lung | 12 | 2021 | 3664 | 0.790 |
Why?
| | Human Migration | 2 | 2020 | 21 | 0.760 |
Why?
| | Lipopolysaccharide Receptors | 4 | 2010 | 88 | 0.760 |
Why?
| | Membrane Proteins | 8 | 2018 | 1055 | 0.730 |
Why?
| | Gene Flow | 2 | 2020 | 79 | 0.720 |
Why?
| | Interleukin-10 | 5 | 2017 | 306 | 0.720 |
Why?
| | Antigens, Helminth | 3 | 2019 | 15 | 0.720 |
Why?
| | Transcriptome | 6 | 2023 | 756 | 0.710 |
Why?
| | Chromosomes, Human, Pair 12 | 7 | 2019 | 28 | 0.710 |
Why?
| | Adult | 82 | 2021 | 31512 | 0.680 |
Why?
| | DNA Methylation | 4 | 2023 | 503 | 0.680 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 6 | 2021 | 101 | 0.670 |
Why?
| | Brazil | 12 | 2017 | 109 | 0.660 |
Why?
| | Middle Aged | 67 | 2023 | 27617 | 0.660 |
Why?
| | Cytokines | 7 | 2023 | 1900 | 0.660 |
Why?
| | Rhinitis, Allergic | 2 | 2014 | 37 | 0.610 |
Why?
| | Multifactorial Inheritance | 3 | 2022 | 143 | 0.600 |
Why?
| | Decision Support Systems, Clinical | 1 | 2020 | 178 | 0.600 |
Why?
| | Academic Medical Centers | 1 | 2020 | 422 | 0.600 |
Why?
| | Scleroderma, Systemic | 2 | 2016 | 94 | 0.590 |
Why?
| | Quantitative Trait Loci | 9 | 2022 | 324 | 0.590 |
Why?
| | Oligonucleotide Array Sequence Analysis | 8 | 2017 | 770 | 0.590 |
Why?
| | Interferon-gamma | 6 | 2015 | 736 | 0.580 |
Why?
| | Exome | 5 | 2022 | 220 | 0.580 |
Why?
| | Schistosoma mansoni | 6 | 2017 | 39 | 0.570 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2017 | 164 | 0.550 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2015 | 81 | 0.520 |
Why?
| | Duffy Blood-Group System | 2 | 2008 | 7 | 0.520 |
Why?
| | Genetic Markers | 11 | 2020 | 348 | 0.520 |
Why?
| | Forced Expiratory Volume | 5 | 2020 | 520 | 0.510 |
Why?
| | Adenosine Triphosphatases | 1 | 2016 | 158 | 0.510 |
Why?
| | Allergens | 9 | 2023 | 424 | 0.510 |
Why?
| | Schistosomiasis mansoni | 5 | 2012 | 24 | 0.510 |
Why?
| | Adolescent | 48 | 2021 | 18480 | 0.490 |
Why?
| | Genomics | 9 | 2024 | 706 | 0.490 |
Why?
| | Minority Groups | 2 | 2019 | 237 | 0.480 |
Why?
| | Endemic Diseases | 5 | 2017 | 28 | 0.480 |
Why?
| | Respiratory Sounds | 2 | 2023 | 119 | 0.470 |
Why?
| | Th2 Cells | 6 | 2023 | 164 | 0.460 |
Why?
| | Insurance, Health | 1 | 2015 | 244 | 0.460 |
Why?
| | Mosaicism | 3 | 2023 | 62 | 0.460 |
Why?
| | Smoking | 7 | 2022 | 1487 | 0.460 |
Why?
| | Child | 47 | 2023 | 19129 | 0.460 |
Why?
| | Myosin-Light-Chain Kinase | 3 | 2007 | 26 | 0.450 |
Why?
| | Germ-Line Mutation | 3 | 2023 | 134 | 0.450 |
Why?
| | Interleukin-13 | 6 | 2023 | 135 | 0.450 |
Why?
| | Ankyrins | 1 | 2012 | 7 | 0.440 |
Why?
| | Schistosoma japonicum | 3 | 2019 | 36 | 0.440 |
Why?
| | Hepatocyte Nuclear Factor 3-alpha | 1 | 2012 | 11 | 0.440 |
Why?
| | Loss of Function Mutation | 3 | 2021 | 42 | 0.440 |
Why?
| | CpG Islands | 5 | 2023 | 119 | 0.440 |
Why?
| | Helminths | 1 | 2012 | 8 | 0.440 |
Why?
| | Pedigree | 7 | 2020 | 485 | 0.430 |
Why?
| | Interferon Regulatory Factor-2 | 1 | 2011 | 5 | 0.420 |
Why?
| | Child, Preschool | 25 | 2021 | 9491 | 0.420 |
Why?
| | Ambulatory Care | 1 | 2015 | 482 | 0.410 |
Why?
| | Receptors, Interleukin-6 | 1 | 2011 | 36 | 0.410 |
Why?
| | Aquaporin 5 | 1 | 2010 | 5 | 0.390 |
Why?
| | Mites | 6 | 2009 | 9 | 0.390 |
Why?
| | Aged | 35 | 2022 | 19657 | 0.390 |
Why?
| | Hypertension, Pulmonary | 4 | 2016 | 1794 | 0.390 |
Why?
| | Genetic Heterogeneity | 3 | 2016 | 56 | 0.390 |
Why?
| | Cockroaches | 1 | 2010 | 23 | 0.380 |
Why?
| | Colombia | 6 | 2020 | 43 | 0.380 |
Why?
| | Receptors, Interleukin-7 | 1 | 2010 | 26 | 0.370 |
Why?
| | Receptors, Cytokine | 1 | 2010 | 33 | 0.370 |
Why?
| | Chromosomes, Human, Pair 19 | 3 | 2012 | 25 | 0.370 |
Why?
| | Young Adult | 27 | 2022 | 10793 | 0.370 |
Why?
| | Respiration | 3 | 2017 | 183 | 0.370 |
Why?
| | United States | 22 | 2021 | 12555 | 0.370 |
Why?
| | Promoter Regions, Genetic | 7 | 2023 | 1158 | 0.360 |
Why?
| | Receptors, Cell Surface | 2 | 2009 | 367 | 0.360 |
Why?
| | Epigenesis, Genetic | 6 | 2023 | 539 | 0.360 |
Why?
| | Receptors, Leptin | 1 | 2009 | 27 | 0.340 |
Why?
| | Interferon-alpha | 1 | 2010 | 191 | 0.340 |
Why?
| | Antibodies, Helminth | 4 | 2019 | 11 | 0.340 |
Why?
| | Biomarkers | 11 | 2023 | 3588 | 0.340 |
Why?
| | Autoimmune Diseases | 1 | 2012 | 398 | 0.330 |
Why?
| | Primary Health Care | 2 | 2016 | 1560 | 0.330 |
Why?
| | Nuclear Family | 6 | 2003 | 54 | 0.330 |
Why?
| | Risk Factors | 18 | 2022 | 9000 | 0.330 |
Why?
| | Multigene Family | 5 | 2013 | 200 | 0.320 |
Why?
| | Disease Susceptibility | 5 | 2018 | 331 | 0.320 |
Why?
| | Fatty Acid Desaturases | 3 | 2014 | 34 | 0.320 |
Why?
| | Immunotherapy | 1 | 2012 | 493 | 0.320 |
Why?
| | Gene Expression Regulation | 11 | 2018 | 2445 | 0.300 |
Why?
| | Odds Ratio | 5 | 2017 | 996 | 0.300 |
Why?
| | Sequence Analysis, DNA | 5 | 2016 | 755 | 0.300 |
Why?
| | Animals | 38 | 2023 | 33381 | 0.300 |
Why?
| | Schistosomiasis japonica | 2 | 2019 | 36 | 0.300 |
Why?
| | Proteins | 2 | 2010 | 938 | 0.290 |
Why?
| | Cohort Studies | 13 | 2023 | 5116 | 0.290 |
Why?
| | Peanut Hypersensitivity | 2 | 2022 | 204 | 0.290 |
Why?
| | Sample Size | 4 | 2022 | 133 | 0.290 |
Why?
| | Severity of Illness Index | 12 | 2023 | 2674 | 0.290 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2006 | 18 | 0.290 |
Why?
| | Skin | 6 | 2023 | 657 | 0.280 |
Why?
| | Models, Statistical | 5 | 2021 | 636 | 0.270 |
Why?
| | Chromosomes, Human, Pair 17 | 4 | 2019 | 63 | 0.270 |
Why?
| | Parasitic Diseases | 1 | 2005 | 8 | 0.270 |
Why?
| | Chromosomes, Human, Pair 6 | 2 | 2012 | 47 | 0.270 |
Why?
| | Skin Tests | 7 | 2017 | 135 | 0.270 |
Why?
| | Caribbean Region | 4 | 2011 | 24 | 0.270 |
Why?
| | Internship and Residency | 1 | 2015 | 1001 | 0.270 |
Why?
| | Tobacco Use | 2 | 2023 | 58 | 0.270 |
Why?
| | Hematopoiesis | 2 | 2023 | 175 | 0.260 |
Why?
| | Dust | 2 | 2005 | 88 | 0.260 |
Why?
| | Models, Genetic | 9 | 2021 | 595 | 0.260 |
Why?
| | Algorithms | 4 | 2021 | 1541 | 0.260 |
Why?
| | Immunoglobulin G | 3 | 2022 | 788 | 0.260 |
Why?
| | Consanguinity | 2 | 2005 | 49 | 0.250 |
Why?
| | Complement C3 | 1 | 2006 | 192 | 0.250 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2017 | 453 | 0.250 |
Why?
| | DNA Mutational Analysis | 6 | 2021 | 381 | 0.250 |
Why?
| | Leukocytes | 3 | 2021 | 290 | 0.250 |
Why?
| | Liver Cirrhosis | 2 | 2017 | 245 | 0.240 |
Why?
| | HLA-DQ alpha-Chains | 2 | 2022 | 17 | 0.240 |
Why?
| | Endotoxins | 1 | 2005 | 234 | 0.240 |
Why?
| | Microtubule-Associated Proteins | 2 | 2018 | 188 | 0.240 |
Why?
| | Immunity, Innate | 4 | 2014 | 745 | 0.240 |
Why?
| | Respiratory Physiological Phenomena | 2 | 2020 | 31 | 0.240 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2017 | 984 | 0.240 |
Why?
| | Internationality | 2 | 2022 | 152 | 0.240 |
Why?
| | Risk | 9 | 2019 | 853 | 0.240 |
Why?
| | Receptors, Complement | 1 | 2004 | 115 | 0.230 |
Why?
| | Ectropion | 1 | 2023 | 3 | 0.230 |
Why?
| | Blepharitis | 1 | 2023 | 4 | 0.230 |
Why?
| | Receptors, Interferon | 2 | 2015 | 49 | 0.230 |
Why?
| | Xanthine Dehydrogenase | 1 | 2023 | 34 | 0.230 |
Why?
| | Point Mutation | 1 | 2004 | 228 | 0.230 |
Why?
| | Chromosome Aberrations | 2 | 2015 | 136 | 0.230 |
Why?
| | Conjunctivitis | 1 | 2023 | 19 | 0.230 |
Why?
| | Geography | 2 | 2016 | 190 | 0.230 |
Why?
| | Drug Repositioning | 1 | 2023 | 14 | 0.230 |
Why?
| | Gene Expression | 6 | 2018 | 1489 | 0.230 |
Why?
| | Tight Junctions | 3 | 2012 | 69 | 0.220 |
Why?
| | Infant | 10 | 2021 | 8293 | 0.220 |
Why?
| | Heart Injuries | 1 | 2023 | 38 | 0.220 |
Why?
| | Mice | 18 | 2023 | 15520 | 0.220 |
Why?
| | Software | 4 | 2021 | 613 | 0.220 |
Why?
| | Hematopoietic Stem Cells | 2 | 2023 | 359 | 0.220 |
Why?
| | Arachis | 2 | 2022 | 152 | 0.220 |
Why?
| | Aged, 80 and over | 14 | 2020 | 6561 | 0.220 |
Why?
| | Antigens, Plant | 2 | 2022 | 53 | 0.220 |
Why?
| | Vital Capacity | 2 | 2020 | 260 | 0.210 |
Why?
| | Pseudomonas Infections | 2 | 2015 | 193 | 0.210 |
Why?
| | Computational Biology | 2 | 2024 | 588 | 0.210 |
Why?
| | Eczema | 1 | 2023 | 85 | 0.210 |
Why?
| | Reperfusion Injury | 3 | 2010 | 276 | 0.210 |
Why?
| | HLA-D Antigens | 2 | 1998 | 36 | 0.210 |
Why?
| | 2S Albumins, Plant | 1 | 2022 | 29 | 0.210 |
Why?
| | Cystic Fibrosis | 3 | 2018 | 964 | 0.210 |
Why?
| | Herpesvirus 1, Human | 2 | 2021 | 81 | 0.200 |
Why?
| | Leukocytes, Mononuclear | 4 | 2013 | 509 | 0.200 |
Why?
| | Intermediate Filament Proteins | 3 | 2018 | 69 | 0.200 |
Why?
| | Nucleotide Transport Proteins | 1 | 2021 | 3 | 0.200 |
Why?
| | Dinoprostone | 1 | 2022 | 193 | 0.200 |
Why?
| | Quantitative Trait, Heritable | 1 | 2002 | 119 | 0.200 |
Why?
| | Neoplasm Proteins | 3 | 2022 | 401 | 0.190 |
Why?
| | Islands | 1 | 2020 | 5 | 0.190 |
Why?
| | Indians, Central American | 1 | 2020 | 7 | 0.190 |
Why?
| | Cluster Analysis | 3 | 2018 | 481 | 0.190 |
Why?
| | Indians, South American | 1 | 2020 | 23 | 0.190 |
Why?
| | Fatty Acids, Omega-6 | 2 | 2011 | 48 | 0.190 |
Why?
| | Receptors, Nicotinic | 2 | 2013 | 295 | 0.190 |
Why?
| | Antibody Formation | 1 | 2022 | 276 | 0.190 |
Why?
| | Cytochrome P-450 CYP2C19 | 1 | 2020 | 21 | 0.190 |
Why?
| | Amish | 1 | 2020 | 8 | 0.190 |
Why?
| | Liver | 3 | 2020 | 1816 | 0.180 |
Why?
| | beta-Globins | 1 | 2019 | 16 | 0.180 |
Why?
| | Prevalence | 5 | 2019 | 2326 | 0.180 |
Why?
| | Health Status Disparities | 2 | 2019 | 209 | 0.180 |
Why?
| | Glycoproteins | 2 | 1998 | 319 | 0.180 |
Why?
| | Respiratory Function Tests | 4 | 2018 | 526 | 0.180 |
Why?
| | HLA-DRB1 Chains | 1 | 2020 | 97 | 0.180 |
Why?
| | Interferon Regulatory Factors | 1 | 2019 | 31 | 0.180 |
Why?
| | Mutation | 9 | 2023 | 3457 | 0.180 |
Why?
| | Base Sequence | 3 | 2016 | 2159 | 0.180 |
Why?
| | Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein | 1 | 2019 | 3 | 0.170 |
Why?
| | Polymerase Chain Reaction | 3 | 2010 | 1012 | 0.170 |
Why?
| | Apolipoprotein L1 | 1 | 2018 | 15 | 0.170 |
Why?
| | Sex Characteristics | 3 | 2014 | 671 | 0.170 |
Why?
| | Europe | 5 | 2022 | 356 | 0.170 |
Why?
| | Chromosomes, Human, Pair 18 | 1 | 2018 | 12 | 0.170 |
Why?
| | HLA Antigens | 1 | 2020 | 230 | 0.170 |
Why?
| | Smad2 Protein | 1 | 2018 | 39 | 0.170 |
Why?
| | Pulmonary Emphysema | 2 | 2014 | 327 | 0.160 |
Why?
| | Cell Adhesion Molecules | 1 | 2019 | 180 | 0.160 |
Why?
| | Computer Communication Networks | 1 | 2018 | 33 | 0.160 |
Why?
| | Delivery of Health Care | 3 | 2023 | 867 | 0.160 |
Why?
| | Dyneins | 1 | 2018 | 30 | 0.160 |
Why?
| | Clinical Trials as Topic | 3 | 2012 | 969 | 0.160 |
Why?
| | Staphylococcal Skin Infections | 1 | 2018 | 30 | 0.160 |
Why?
| | Molecular Epidemiology | 3 | 2013 | 69 | 0.160 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 1 | 2017 | 33 | 0.160 |
Why?
| | Molecular Targeted Therapy | 1 | 2020 | 356 | 0.160 |
Why?
| | Mendelian Randomization Analysis | 1 | 2017 | 48 | 0.150 |
Why?
| | Specimen Handling | 1 | 2018 | 165 | 0.150 |
Why?
| | Acute Lung Injury | 2 | 2012 | 310 | 0.150 |
Why?
| | Information Storage and Retrieval | 1 | 2018 | 124 | 0.150 |
Why?
| | Eosinophils | 1 | 2019 | 282 | 0.150 |
Why?
| | Gene Regulatory Networks | 3 | 2014 | 239 | 0.150 |
Why?
| | Interviews as Topic | 1 | 1999 | 599 | 0.150 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2016 | 333 | 0.150 |
Why?
| | Colorado | 3 | 2024 | 4196 | 0.150 |
Why?
| | Interleukin-1 Receptor-Like 1 Protein | 1 | 2017 | 24 | 0.150 |
Why?
| | Women's Health | 1 | 2019 | 274 | 0.150 |
Why?
| | Databases, Genetic | 3 | 2019 | 253 | 0.150 |
Why?
| | Evolution, Molecular | 2 | 2012 | 454 | 0.150 |
Why?
| | United Kingdom | 3 | 2021 | 236 | 0.150 |
Why?
| | Antibody Specificity | 4 | 2009 | 184 | 0.150 |
Why?
| | Alcohol Drinking | 1 | 2022 | 652 | 0.150 |
Why?
| | RNA, Messenger | 4 | 2016 | 2657 | 0.150 |
Why?
| | Enhancer Elements, Genetic | 1 | 2017 | 152 | 0.150 |
Why?
| | DNA, Intergenic | 1 | 2016 | 25 | 0.150 |
Why?
| | Cilia | 1 | 2018 | 160 | 0.150 |
Why?
| | Schistosomiasis | 1 | 2017 | 38 | 0.140 |
Why?
| | Chromosomes, Human, Pair 14 | 2 | 2014 | 17 | 0.140 |
Why?
| | Sexism | 1 | 2016 | 45 | 0.140 |
Why?
| | Immunity | 2 | 2010 | 129 | 0.140 |
Why?
| | Disease Progression | 6 | 2019 | 2490 | 0.140 |
Why?
| | Biomedical Research | 2 | 2020 | 612 | 0.140 |
Why?
| | Adrenal Cortex Hormones | 1 | 2019 | 521 | 0.140 |
Why?
| | Bronchodilator Agents | 2 | 2015 | 253 | 0.140 |
Why?
| | Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I | 1 | 2015 | 1 | 0.140 |
Why?
| | Myocardial Infarction | 1 | 2023 | 968 | 0.140 |
Why?
| | Heterozygote | 3 | 2021 | 262 | 0.140 |
Why?
| | Genes, Modifier | 1 | 2015 | 2 | 0.130 |
Why?
| | Caveolin 2 | 1 | 2015 | 4 | 0.130 |
Why?
| | Matrix Metalloproteinase 1 | 1 | 2015 | 23 | 0.130 |
Why?
| | alpha 1-Antitrypsin Deficiency | 1 | 2016 | 79 | 0.130 |
Why?
| | Toll-Like Receptor 2 | 2 | 2014 | 127 | 0.130 |
Why?
| | Computer Simulation | 3 | 2012 | 922 | 0.130 |
Why?
| | Surveys and Questionnaires | 5 | 2020 | 4708 | 0.130 |
Why?
| | Endostatins | 1 | 2015 | 11 | 0.130 |
Why?
| | Collagen Type XVIII | 1 | 2015 | 5 | 0.130 |
Why?
| | Host-Parasite Interactions | 2 | 2015 | 110 | 0.130 |
Why?
| | Biological Evolution | 1 | 2019 | 443 | 0.130 |
Why?
| | Prognosis | 5 | 2021 | 3443 | 0.130 |
Why?
| | Immune System Diseases | 1 | 2014 | 35 | 0.130 |
Why?
| | Chromosome Disorders | 1 | 2014 | 39 | 0.130 |
Why?
| | alpha-N-Acetylgalactosaminidase | 1 | 2014 | 3 | 0.130 |
Why?
| | Urbanization | 2 | 2011 | 25 | 0.130 |
Why?
| | Age of Onset | 5 | 2015 | 467 | 0.120 |
Why?
| | Physicians, Family | 1 | 2016 | 206 | 0.120 |
Why?
| | Staphylococcus aureus | 1 | 2018 | 394 | 0.120 |
Why?
| | Kidney Diseases | 1 | 2018 | 439 | 0.120 |
Why?
| | Extracellular Matrix Proteins | 1 | 2015 | 133 | 0.120 |
Why?
| | Phospholipase C beta | 1 | 2014 | 26 | 0.120 |
Why?
| | Helicobacter Infections | 1 | 2014 | 25 | 0.120 |
Why?
| | Helicobacter pylori | 1 | 2014 | 31 | 0.120 |
Why?
| | Reproducibility of Results | 5 | 2017 | 2874 | 0.120 |
Why?
| | Apolipoprotein E4 | 1 | 2014 | 37 | 0.120 |
Why?
| | Time Factors | 7 | 2020 | 6412 | 0.120 |
Why?
| | Colitis, Ulcerative | 1 | 2015 | 105 | 0.120 |
Why?
| | Integrin beta Chains | 1 | 2013 | 7 | 0.120 |
Why?
| | HLA-B7 Antigen | 1 | 2013 | 8 | 0.120 |
Why?
| | STAT5 Transcription Factor | 1 | 2014 | 43 | 0.120 |
Why?
| | Transmembrane Activator and CAML Interactor Protein | 1 | 2013 | 4 | 0.120 |
Why?
| | beta-Defensins | 1 | 2013 | 22 | 0.120 |
Why?
| | Pseudomonas aeruginosa | 2 | 2015 | 305 | 0.120 |
Why?
| | Chemokines, CC | 1 | 2013 | 30 | 0.120 |
Why?
| | Vaccinia virus | 2 | 2011 | 34 | 0.120 |
Why?
| | Nuclear Pore Complex Proteins | 1 | 2013 | 34 | 0.120 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2015 | 176 | 0.120 |
Why?
| | Genome | 2 | 2006 | 277 | 0.120 |
Why?
| | Jamaica | 1 | 2013 | 3 | 0.120 |
Why?
| | Tobacco Use Disorder | 2 | 2013 | 233 | 0.120 |
Why?
| | Data Interpretation, Statistical | 2 | 2012 | 336 | 0.120 |
Why?
| | District of Columbia | 1 | 2013 | 27 | 0.120 |
Why?
| | Kv Channel-Interacting Proteins | 1 | 2013 | 4 | 0.110 |
Why?
| | Chemokine CXCL12 | 1 | 2013 | 80 | 0.110 |
Why?
| | Virginia | 2 | 2005 | 52 | 0.110 |
Why?
| | Sputum | 1 | 2015 | 290 | 0.110 |
Why?
| | Microsatellite Repeats | 3 | 2009 | 143 | 0.110 |
Why?
| | Gene Order | 1 | 2012 | 28 | 0.110 |
Why?
| | Mast Cells | 1 | 2014 | 115 | 0.110 |
Why?
| | New York | 1 | 2013 | 118 | 0.110 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2012 | 20 | 0.110 |
Why?
| | Kallikreins | 1 | 2012 | 33 | 0.110 |
Why?
| | Phylogeny | 1 | 2016 | 816 | 0.110 |
Why?
| | Telomerase | 1 | 2014 | 207 | 0.110 |
Why?
| | Environment | 3 | 2011 | 346 | 0.110 |
Why?
| | Family Health | 4 | 2006 | 201 | 0.110 |
Why?
| | Erythroid Cells | 1 | 2012 | 9 | 0.110 |
Why?
| | Obesity | 2 | 2018 | 2746 | 0.110 |
Why?
| | Research | 1 | 2015 | 411 | 0.110 |
Why?
| | Cross-Sectional Studies | 6 | 2022 | 4552 | 0.110 |
Why?
| | Family Practice | 1 | 2016 | 438 | 0.110 |
Why?
| | Antigens, Dermatophagoides | 5 | 2009 | 15 | 0.110 |
Why?
| | Epidermis | 1 | 2012 | 152 | 0.100 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2015 | 228 | 0.100 |
Why?
| | Nerve Tissue Proteins | 2 | 2013 | 551 | 0.100 |
Why?
| | Cell Line | 3 | 2015 | 2707 | 0.100 |
Why?
| | Skin Diseases, Viral | 1 | 2011 | 5 | 0.100 |
Why?
| | Prostate-Specific Antigen | 1 | 2012 | 156 | 0.100 |
Why?
| | Kidney | 2 | 2010 | 1353 | 0.100 |
Why?
| | STAT6 Transcription Factor | 1 | 2011 | 22 | 0.100 |
Why?
| | Immunity, Cellular | 1 | 2013 | 270 | 0.100 |
Why?
| | Physician-Patient Relations | 1 | 2016 | 490 | 0.100 |
Why?
| | Rare Diseases | 1 | 2012 | 113 | 0.100 |
Why?
| | Costa Rica | 3 | 2019 | 19 | 0.100 |
Why?
| | Lipopolysaccharides | 3 | 2014 | 870 | 0.100 |
Why?
| | Immunomodulation | 1 | 2012 | 89 | 0.100 |
Why?
| | Simplexvirus | 1 | 2011 | 86 | 0.100 |
Why?
| | Wound Healing | 2 | 2012 | 270 | 0.100 |
Why?
| | Chromosomes, Human | 2 | 2009 | 41 | 0.100 |
Why?
| | Lod Score | 6 | 2009 | 75 | 0.100 |
Why?
| | Peru | 3 | 2021 | 59 | 0.100 |
Why?
| | Genetic Pleiotropy | 1 | 2011 | 31 | 0.100 |
Why?
| | Stearoyl-CoA Desaturase | 1 | 2011 | 57 | 0.100 |
Why?
| | Healthcare Disparities | 1 | 2016 | 496 | 0.100 |
Why?
| | Myeloblastin | 1 | 2010 | 9 | 0.100 |
Why?
| | Up-Regulation | 3 | 2014 | 872 | 0.100 |
Why?
| | Myelopoiesis | 1 | 2010 | 8 | 0.100 |
Why?
| | Membrane Glycoproteins | 2 | 2010 | 446 | 0.090 |
Why?
| | Mutagenesis | 2 | 2021 | 176 | 0.090 |
Why?
| | Mice, Knockout | 3 | 2012 | 2680 | 0.090 |
Why?
| | Immunohistochemistry | 3 | 2010 | 1691 | 0.090 |
Why?
| | Goals | 1 | 2011 | 167 | 0.090 |
Why?
| | Death Domain Receptor Signaling Adaptor Proteins | 1 | 2009 | 4 | 0.090 |
Why?
| | RNA-Binding Proteins | 1 | 2013 | 371 | 0.090 |
Why?
| | Family | 3 | 2009 | 585 | 0.090 |
Why?
| | Markov Chains | 1 | 2010 | 118 | 0.090 |
Why?
| | Environmental Exposure | 2 | 2011 | 405 | 0.090 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 1 | 2010 | 34 | 0.090 |
Why?
| | Urban Population | 1 | 2012 | 409 | 0.090 |
Why?
| | Mannose-Binding Lectins | 1 | 2009 | 14 | 0.090 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2010 | 43 | 0.090 |
Why?
| | Chromosomes, Human, Pair 5 | 2 | 2000 | 26 | 0.090 |
Why?
| | Lectins | 1 | 2010 | 50 | 0.090 |
Why?
| | Coculture Techniques | 1 | 2010 | 208 | 0.090 |
Why?
| | Lectins, C-Type | 1 | 2009 | 63 | 0.090 |
Why?
| | Plasmids | 1 | 2010 | 355 | 0.090 |
Why?
| | ADAM Proteins | 1 | 2009 | 59 | 0.090 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2009 | 74 | 0.090 |
Why?
| | Chemokine CCL5 | 2 | 2000 | 48 | 0.090 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2009 | 7 | 0.090 |
Why?
| | Toll-Like Receptor 4 | 2 | 2014 | 330 | 0.090 |
Why?
| | Guanine Nucleotide Exchange Factors | 1 | 2009 | 59 | 0.090 |
Why?
| | Chromosomes, Human, Y | 1 | 2009 | 15 | 0.090 |
Why?
| | Quality Control | 3 | 2021 | 159 | 0.090 |
Why?
| | Africa | 3 | 2020 | 100 | 0.090 |
Why?
| | Down-Regulation | 2 | 2015 | 627 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2010 | 115 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2020 | 1798 | 0.080 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2012 | 394 | 0.080 |
Why?
| | Anxiety | 1 | 2015 | 845 | 0.080 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2009 | 53 | 0.080 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 827 | 0.080 |
Why?
| | Adaptation, Physiological | 1 | 2012 | 502 | 0.080 |
Why?
| | Informed Consent | 2 | 2020 | 163 | 0.080 |
Why?
| | Infant, Newborn | 5 | 2012 | 5255 | 0.080 |
Why?
| | Genotyping Techniques | 2 | 2019 | 75 | 0.080 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2014 | 468 | 0.080 |
Why?
| | Proteoglycans | 1 | 2009 | 109 | 0.080 |
Why?
| | Tissue Donors | 1 | 2010 | 336 | 0.080 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2013 | 702 | 0.080 |
Why?
| | Spirometry | 3 | 2017 | 263 | 0.080 |
Why?
| | Hydrolases | 1 | 2008 | 51 | 0.080 |
Why?
| | Dietary Fats | 1 | 2010 | 322 | 0.080 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2020 | 404 | 0.080 |
Why?
| | DNA, Mitochondrial | 1 | 2009 | 187 | 0.080 |
Why?
| | Recombinant Fusion Proteins | 1 | 2010 | 653 | 0.080 |
Why?
| | CD4 Antigens | 1 | 2008 | 126 | 0.080 |
Why?
| | Emergency Service, Hospital | 1 | 2018 | 1864 | 0.080 |
Why?
| | China | 2 | 2019 | 175 | 0.080 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2009 | 200 | 0.080 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2008 | 127 | 0.080 |
Why?
| | Social Class | 1 | 2009 | 218 | 0.080 |
Why?
| | Workflow | 2 | 2018 | 148 | 0.080 |
Why?
| | Antigens, CD | 1 | 2010 | 460 | 0.080 |
Why?
| | Bias | 2 | 2020 | 198 | 0.080 |
Why?
| | Stress, Psychological | 1 | 2015 | 972 | 0.080 |
Why?
| | Dendritic Cells | 1 | 2010 | 442 | 0.070 |
Why?
| | Air Pollutants | 1 | 2011 | 316 | 0.070 |
Why?
| | Cyclic AMP-Dependent Protein Kinase RIIbeta Subunit | 1 | 2006 | 1 | 0.070 |
Why?
| | Cyclic AMP-Dependent Protein Kinase RIalpha Subunit | 1 | 2006 | 2 | 0.070 |
Why?
| | Registries | 1 | 2014 | 1810 | 0.070 |
Why?
| | Cell Nucleus | 1 | 2010 | 580 | 0.070 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2009 | 359 | 0.070 |
Why?
| | Genes, Neoplasm | 1 | 2006 | 21 | 0.070 |
Why?
| | Germany | 2 | 2004 | 89 | 0.070 |
Why?
| | Renal Circulation | 1 | 2006 | 75 | 0.070 |
Why?
| | Chromosomes, Human, Pair 2 | 1 | 2006 | 28 | 0.070 |
Why?
| | Computer Graphics | 1 | 2006 | 48 | 0.070 |
Why?
| | Pollen | 1 | 2006 | 27 | 0.070 |
Why?
| | Body Mass Index | 3 | 2022 | 2092 | 0.070 |
Why?
| | Body Height | 2 | 2019 | 187 | 0.070 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2006 | 140 | 0.070 |
Why?
| | Longitudinal Studies | 3 | 2018 | 2513 | 0.070 |
Why?
| | Likelihood Functions | 1 | 2005 | 136 | 0.070 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2006 | 290 | 0.060 |
Why?
| | Mucins | 1 | 2005 | 59 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2008 | 527 | 0.060 |
Why?
| | Keratinocytes | 3 | 2012 | 227 | 0.060 |
Why?
| | B-Lymphocytes | 1 | 2010 | 770 | 0.060 |
Why?
| | Receptors, Prostaglandin | 1 | 2004 | 26 | 0.060 |
Why?
| | Inflammation | 2 | 2023 | 2566 | 0.060 |
Why?
| | Immunoglobulins | 1 | 2005 | 154 | 0.060 |
Why?
| | U937 Cells | 1 | 2004 | 26 | 0.060 |
Why?
| | Sex Factors | 3 | 2014 | 1781 | 0.060 |
Why?
| | Autoantibodies | 2 | 2010 | 1335 | 0.060 |
Why?
| | Transcription, Genetic | 3 | 2021 | 1323 | 0.060 |
Why?
| | Receptor, Anaphylatoxin C5a | 1 | 2004 | 30 | 0.060 |
Why?
| | Wounds and Injuries | 1 | 2012 | 772 | 0.060 |
Why?
| | Mice, Inbred C57BL | 5 | 2014 | 4908 | 0.060 |
Why?
| | Cells, Cultured | 4 | 2014 | 4077 | 0.060 |
Why?
| | Family Characteristics | 1 | 2005 | 156 | 0.060 |
Why?
| | Acari | 1 | 2003 | 1 | 0.060 |
Why?
| | Linear Models | 2 | 2017 | 827 | 0.060 |
Why?
| | Pyroglyphidae | 1 | 2003 | 17 | 0.060 |
Why?
| | Receptors, Immunologic | 1 | 2004 | 209 | 0.060 |
Why?
| | Indians, North American | 1 | 2009 | 598 | 0.060 |
Why?
| | Troponin | 1 | 2023 | 47 | 0.060 |
Why?
| | Logistic Models | 3 | 2015 | 1901 | 0.060 |
Why?
| | Pore Forming Cytotoxic Proteins | 1 | 2022 | 16 | 0.060 |
Why?
| | Pruritus | 1 | 2023 | 60 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 982 | 0.060 |
Why?
| | Follow-Up Studies | 3 | 2020 | 4596 | 0.050 |
Why?
| | Autoimmunity | 1 | 2008 | 831 | 0.050 |
Why?
| | Anthropometry | 1 | 2022 | 194 | 0.050 |
Why?
| | Aging | 1 | 2012 | 1670 | 0.050 |
Why?
| | Eicosanoids | 1 | 2022 | 57 | 0.050 |
Why?
| | DNA Demethylation | 1 | 2021 | 2 | 0.050 |
Why?
| | Neoplasms | 2 | 2015 | 2179 | 0.050 |
Why?
| | Biology | 1 | 2023 | 83 | 0.050 |
Why?
| | Pilot Projects | 2 | 2022 | 1419 | 0.050 |
Why?
| | Molecular Sequence Data | 2 | 2004 | 2871 | 0.050 |
Why?
| | Pulmonary Artery | 1 | 2008 | 1063 | 0.050 |
Why?
| | Transfection | 1 | 2004 | 888 | 0.050 |
Why?
| | Epigenomics | 1 | 2022 | 107 | 0.050 |
Why?
| | Nasal Mucosa | 1 | 2022 | 97 | 0.050 |
Why?
| | Long Interspersed Nucleotide Elements | 1 | 2021 | 23 | 0.050 |
Why?
| | INDEL Mutation | 1 | 2021 | 14 | 0.050 |
Why?
| | Americas | 1 | 2021 | 23 | 0.050 |
Why?
| | Amino Acid Sequence | 1 | 2005 | 2071 | 0.050 |
Why?
| | Spain | 1 | 2021 | 34 | 0.050 |
Why?
| | Germ Cells | 1 | 2021 | 64 | 0.050 |
Why?
| | Claudin-1 | 2 | 2011 | 17 | 0.050 |
Why?
| | Mutation, Missense | 1 | 2023 | 300 | 0.050 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2021 | 25 | 0.050 |
Why?
| | Chromosomes, Human, Pair 13 | 1 | 2000 | 18 | 0.050 |
Why?
| | Small Ubiquitin-Related Modifier Proteins | 1 | 2020 | 8 | 0.050 |
Why?
| | Protein Inhibitors of Activated STAT | 1 | 2020 | 8 | 0.050 |
Why?
| | Receptors, LDL | 1 | 2020 | 40 | 0.050 |
Why?
| | Consent Forms | 1 | 2020 | 12 | 0.050 |
Why?
| | Glutathione Transferase | 1 | 2021 | 97 | 0.050 |
Why?
| | Immunoblotting | 2 | 1998 | 307 | 0.050 |
Why?
| | Administration, Inhalation | 2 | 2019 | 656 | 0.050 |
Why?
| | alpha Karyopherins | 1 | 2020 | 15 | 0.050 |
Why?
| | Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2020 | 23 | 0.050 |
Why?
| | Tripartite Motif Proteins | 1 | 2020 | 31 | 0.050 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2022 | 369 | 0.050 |
Why?
| | Polynesia | 1 | 2020 | 4 | 0.050 |
Why?
| | DNA-Binding Proteins | 2 | 2020 | 1346 | 0.050 |
Why?
| | Gene Targeting | 1 | 2020 | 80 | 0.050 |
Why?
| | Dioxygenases | 1 | 2020 | 26 | 0.050 |
Why?
| | Acute Kidney Injury | 1 | 2008 | 709 | 0.050 |
Why?
| | Population Density | 1 | 2021 | 96 | 0.050 |
Why?
| | Predictive Value of Tests | 3 | 2015 | 1868 | 0.050 |
Why?
| | Central America | 1 | 2020 | 27 | 0.050 |
Why?
| | Meta-Analysis as Topic | 2 | 2012 | 164 | 0.050 |
Why?
| | History, Medieval | 1 | 2020 | 43 | 0.050 |
Why?
| | Cell Self Renewal | 1 | 2020 | 51 | 0.050 |
Why?
| | South America | 1 | 2020 | 56 | 0.050 |
Why?
| | Names | 1 | 2000 | 12 | 0.050 |
Why?
| | Oocytes | 1 | 2021 | 190 | 0.050 |
Why?
| | HLA-DQ Antigens | 1 | 2021 | 176 | 0.050 |
Why?
| | Machine Learning | 1 | 2024 | 331 | 0.050 |
Why?
| | Gene Silencing | 1 | 2020 | 177 | 0.050 |
Why?
| | Histocompatibility Testing | 1 | 2020 | 123 | 0.050 |
Why?
| | DNA Replication | 1 | 2021 | 211 | 0.050 |
Why?
| | A549 Cells | 1 | 2019 | 48 | 0.050 |
Why?
| | Emigration and Immigration | 1 | 2000 | 47 | 0.050 |
Why?
| | North America | 2 | 2011 | 266 | 0.040 |
Why?
| | Arthritis, Rheumatoid | 1 | 2008 | 989 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2001 | 525 | 0.040 |
Why?
| | Genetics, Medical | 1 | 2019 | 26 | 0.040 |
Why?
| | Developing Countries | 2 | 2011 | 255 | 0.040 |
Why?
| | Expert Testimony | 1 | 1999 | 56 | 0.040 |
Why?
| | Probability | 1 | 2020 | 305 | 0.040 |
Why?
| | Information Dissemination | 1 | 2021 | 210 | 0.040 |
Why?
| | Chromosomes, Human, Pair 8 | 1 | 2019 | 32 | 0.040 |
Why?
| | Calcium-Binding Proteins | 1 | 2020 | 217 | 0.040 |
Why?
| | Leukocyte Count | 1 | 1999 | 305 | 0.040 |
Why?
| | Reperfusion | 2 | 2010 | 43 | 0.040 |
Why?
| | DNA Damage | 1 | 2021 | 357 | 0.040 |
Why?
| | Cell Cycle Proteins | 1 | 2022 | 565 | 0.040 |
Why?
| | Observer Variation | 1 | 1999 | 309 | 0.040 |
Why?
| | RNA, Long Noncoding | 1 | 2021 | 161 | 0.040 |
Why?
| | Oligonucleotides | 1 | 1999 | 140 | 0.040 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2018 | 10 | 0.040 |
Why?
| | Exons | 2 | 2012 | 307 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2002 | 693 | 0.040 |
Why?
| | Health Equity | 1 | 2019 | 56 | 0.040 |
Why?
| | Double-Blind Method | 2 | 2014 | 1687 | 0.040 |
Why?
| | Colony Count, Microbial | 1 | 2018 | 120 | 0.040 |
Why?
| | Proteome | 1 | 2021 | 353 | 0.040 |
Why?
| | Histone Code | 1 | 2017 | 29 | 0.040 |
Why?
| | Rhinitis, Allergic, Seasonal | 1 | 2017 | 32 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2020 | 749 | 0.040 |
Why?
| | Rabbits | 1 | 2019 | 780 | 0.040 |
Why?
| | Socioeconomic Factors | 2 | 2012 | 1129 | 0.040 |
Why?
| | Eosinophilia | 1 | 1999 | 184 | 0.040 |
Why?
| | Mice, Transgenic | 2 | 2014 | 2025 | 0.040 |
Why?
| | Western Australia | 1 | 2017 | 6 | 0.040 |
Why?
| | Dermatophagoides pteronyssinus | 2 | 2009 | 5 | 0.040 |
Why?
| | T-Lymphocytes | 1 | 2005 | 1774 | 0.040 |
Why?
| | Program Evaluation | 1 | 2021 | 845 | 0.040 |
Why?
| | West Indies | 1 | 1996 | 6 | 0.040 |
Why?
| | Data Accuracy | 1 | 2017 | 56 | 0.040 |
Why?
| | Interleukin-33 | 1 | 2017 | 39 | 0.040 |
Why?
| | Lipids | 1 | 2020 | 607 | 0.040 |
Why?
| | Proto-Oncogene Proteins | 1 | 2020 | 618 | 0.040 |
Why?
| | Binding Sites | 2 | 2010 | 1224 | 0.040 |
Why?
| | Demography | 2 | 2011 | 274 | 0.040 |
Why?
| | Molecular Sequence Annotation | 1 | 2016 | 91 | 0.040 |
Why?
| | Boston | 1 | 2016 | 76 | 0.040 |
Why?
| | DNA | 1 | 2023 | 1388 | 0.030 |
Why?
| | Sarcoglycans | 1 | 2015 | 5 | 0.030 |
Why?
| | Jurkat Cells | 2 | 2010 | 134 | 0.030 |
Why?
| | Rhode Island | 1 | 2015 | 23 | 0.030 |
Why?
| | Puerto Rico | 1 | 2015 | 56 | 0.030 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2015 | 44 | 0.030 |
Why?
| | STAT1 Transcription Factor | 1 | 2015 | 69 | 0.030 |
Why?
| | Medical Informatics | 1 | 2016 | 102 | 0.030 |
Why?
| | Education | 1 | 2015 | 105 | 0.030 |
Why?
| | DNA, Complementary | 2 | 2010 | 268 | 0.030 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2009 | 613 | 0.030 |
Why?
| | Genes, Reporter | 1 | 2015 | 270 | 0.030 |
Why?
| | Blood Chemical Analysis | 1 | 2015 | 95 | 0.030 |
Why?
| | Apolipoprotein E3 | 1 | 2014 | 4 | 0.030 |
Why?
| | Fibrosis | 1 | 2017 | 483 | 0.030 |
Why?
| | Pneumothorax | 1 | 2014 | 48 | 0.030 |
Why?
| | Toll-Like Receptor 5 | 1 | 2014 | 15 | 0.030 |
Why?
| | Smoking Cessation | 1 | 2018 | 360 | 0.030 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2014 | 9 | 0.030 |
Why?
| | Erythrocytes | 1 | 1999 | 641 | 0.030 |
Why?
| | Myosin Heavy Chains | 1 | 2015 | 192 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1355 | 0.030 |
Why?
| | alpha 1-Antitrypsin | 1 | 2014 | 115 | 0.030 |
Why?
| | ROC Curve | 1 | 2015 | 473 | 0.030 |
Why?
| | Cotinine | 1 | 2013 | 76 | 0.030 |
Why?
| | Foreskin | 1 | 2012 | 6 | 0.030 |
Why?
| | Toll-Like Receptor 1 | 1 | 2012 | 12 | 0.030 |
Why?
| | Parasite Load | 1 | 2012 | 8 | 0.030 |
Why?
| | Peptidoglycan | 1 | 2012 | 28 | 0.030 |
Why?
| | Dynactin Complex | 1 | 2012 | 5 | 0.030 |
Why?
| | Polymorphism, Single-Stranded Conformational | 2 | 2004 | 30 | 0.030 |
Why?
| | Transcutaneous Electric Nerve Stimulation | 1 | 2012 | 18 | 0.030 |
Why?
| | Telomere | 1 | 2014 | 204 | 0.030 |
Why?
| | Immunity, Mucosal | 1 | 2013 | 86 | 0.030 |
Why?
| | Permeability | 1 | 2012 | 156 | 0.030 |
Why?
| | Untranslated Regions | 1 | 2012 | 4 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 842 | 0.030 |
Why?
| | Gene Deletion | 1 | 2014 | 361 | 0.030 |
Why?
| | Interleukin-5 | 1 | 2012 | 31 | 0.030 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2012 | 86 | 0.030 |
Why?
| | Ligands | 1 | 2014 | 567 | 0.030 |
Why?
| | Exercise Test | 1 | 2015 | 551 | 0.030 |
Why?
| | Pulmonary Fibrosis | 1 | 2014 | 303 | 0.030 |
Why?
| | Adolescent Development | 1 | 2012 | 84 | 0.030 |
Why?
| | North Carolina | 1 | 2011 | 109 | 0.030 |
Why?
| | Patient Care Team | 1 | 2016 | 521 | 0.030 |
Why?
| | Vaccinia | 1 | 2011 | 19 | 0.030 |
Why?
| | 8,11,14-Eicosatrienoic Acid | 1 | 2011 | 7 | 0.030 |
Why?
| | Smallpox Vaccine | 1 | 2011 | 23 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2015 | 1125 | 0.030 |
Why?
| | Canada | 1 | 2012 | 340 | 0.030 |
Why?
| | Open Reading Frames | 1 | 2012 | 121 | 0.030 |
Why?
| | Rural Health | 1 | 2011 | 72 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2015 | 1474 | 0.020 |
Why?
| | DNA Copy Number Variations | 1 | 2012 | 167 | 0.020 |
Why?
| | P-Selectin | 1 | 2010 | 26 | 0.020 |
Why?
| | Monocytes | 1 | 2014 | 513 | 0.020 |
Why?
| | Physicians | 1 | 1999 | 794 | 0.020 |
Why?
| | Arachidonic Acid | 1 | 2011 | 122 | 0.020 |
Why?
| | Dogs | 2 | 2004 | 371 | 0.020 |
Why?
| | Antibodies, Neutralizing | 1 | 2012 | 228 | 0.020 |
Why?
| | Chronic Disease | 1 | 2017 | 1636 | 0.020 |
Why?
| | Community-Based Participatory Research | 1 | 2011 | 133 | 0.020 |
Why?
| | Gene-Environment Interaction | 1 | 2012 | 201 | 0.020 |
Why?
| | Salmeterol Xinafoate | 1 | 2010 | 42 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2015 | 726 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2011 | 410 | 0.020 |
Why?
| | Vehicle Emissions | 1 | 2011 | 69 | 0.020 |
Why?
| | International Cooperation | 1 | 2011 | 177 | 0.020 |
Why?
| | Genes, RAG-1 | 1 | 2009 | 12 | 0.020 |
Why?
| | Particle Size | 1 | 2011 | 345 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2014 | 688 | 0.020 |
Why?
| | Albuterol | 1 | 2010 | 104 | 0.020 |
Why?
| | Population Groups | 1 | 2010 | 58 | 0.020 |
Why?
| | Protein Array Analysis | 1 | 2010 | 63 | 0.020 |
Why?
| | Air Pollution, Indoor | 1 | 2011 | 117 | 0.020 |
Why?
| | Nicotine | 1 | 2012 | 276 | 0.020 |
Why?
| | Health Surveys | 1 | 2011 | 454 | 0.020 |
Why?
| | Chemokine CCL27 | 1 | 2009 | 2 | 0.020 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2010 | 136 | 0.020 |
Why?
| | Japan | 1 | 2009 | 97 | 0.020 |
Why?
| | Chemokine CCL17 | 1 | 2009 | 5 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2010 | 180 | 0.020 |
Why?
| | Cadaver | 1 | 2010 | 327 | 0.020 |
Why?
| | Herpesvirus 2, Human | 1 | 2009 | 28 | 0.020 |
Why?
| | Isoenzymes | 1 | 2010 | 297 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2009 | 204 | 0.020 |
Why?
| | Chemokine CXCL10 | 1 | 2009 | 40 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 2010 | 415 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2009 | 147 | 0.020 |
Why?
| | Psoriasis | 1 | 2010 | 76 | 0.020 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2010 | 125 | 0.020 |
Why?
| | Parasite Egg Count | 1 | 2008 | 5 | 0.020 |
Why?
| | Interferon-beta | 1 | 2009 | 82 | 0.020 |
Why?
| | RNA | 1 | 2015 | 833 | 0.020 |
Why?
| | Quality of Life | 1 | 2019 | 2366 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2014 | 1171 | 0.020 |
Why?
| | Protein-Arginine Deiminases | 1 | 2008 | 17 | 0.020 |
Why?
| | Regression Analysis | 1 | 2011 | 983 | 0.020 |
Why?
| | Disease | 1 | 2009 | 98 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2011 | 408 | 0.020 |
Why?
| | Incidence | 1 | 2014 | 2424 | 0.020 |
Why?
| | Rural Population | 1 | 2011 | 452 | 0.020 |
Why?
| | Data Collection | 1 | 2011 | 658 | 0.020 |
Why?
| | Self Report | 1 | 2011 | 699 | 0.020 |
Why?
| | Disease Models, Animal | 2 | 2009 | 3730 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3057 | 0.020 |
Why?
| | Hemodynamics | 1 | 2012 | 1003 | 0.020 |
Why?
| | RNA, Complementary | 1 | 2006 | 3 | 0.020 |
Why?
| | Bacterial Proteins | 1 | 2012 | 759 | 0.020 |
Why?
| | Transcription Factors | 1 | 2014 | 1570 | 0.020 |
Why?
| | Feces | 1 | 2008 | 396 | 0.020 |
Why?
| | Age Factors | 1 | 2013 | 2995 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2011 | 892 | 0.020 |
Why?
| | Antibodies, Viral | 1 | 2009 | 542 | 0.020 |
Why?
| | Hepatitis A Antibodies | 1 | 2005 | 4 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2009 | 556 | 0.020 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2005 | 36 | 0.020 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2005 | 29 | 0.020 |
Why?
| | Hepatitis A | 1 | 2005 | 27 | 0.020 |
Why?
| | Nicotinamide Phosphoribosyltransferase | 1 | 2004 | 7 | 0.020 |
Why?
| | Receptors, Virus | 1 | 2005 | 78 | 0.020 |
Why?
| | Introns | 1 | 2006 | 234 | 0.020 |
Why?
| | Major Histocompatibility Complex | 1 | 2006 | 220 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2005 | 146 | 0.020 |
Why?
| | Creatinine | 1 | 2006 | 491 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2006 | 345 | 0.020 |
Why?
| | Chromosomes, Human, Pair 20 | 1 | 2004 | 15 | 0.020 |
Why?
| | NIH 3T3 Cells | 1 | 2004 | 139 | 0.020 |
Why?
| | Kidney Transplantation | 1 | 2010 | 585 | 0.020 |
Why?
| | 3' Untranslated Regions | 1 | 2004 | 142 | 0.010 |
Why?
| | Tropical Climate | 1 | 2003 | 19 | 0.010 |
Why?
| | Seasons | 1 | 2006 | 461 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 1795 | 0.010 |
Why?
| | Reference Values | 1 | 2004 | 774 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2010 | 2851 | 0.010 |
Why?
| | Models, Biological | 1 | 2010 | 1715 | 0.010 |
Why?
| | Housing | 1 | 2003 | 123 | 0.010 |
Why?
| | Pregnancy | 1 | 2014 | 5690 | 0.010 |
Why?
| | Matched-Pair Analysis | 1 | 2001 | 39 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2015 | 9342 | 0.010 |
Why?
| | Sweden | 1 | 2000 | 63 | 0.010 |
Why?
| | Immunization | 1 | 2003 | 412 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2009 | 2436 | 0.010 |
Why?
| | Genetic Testing | 1 | 2001 | 389 | 0.010 |
Why?
| | Cats | 1 | 1998 | 205 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2000 | 874 | 0.010 |
Why?
| | Isoelectric Point | 1 | 1997 | 23 | 0.010 |
Why?
| | Molecular Weight | 1 | 1997 | 343 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1997 | 332 | 0.010 |
Why?
| | Protease Inhibitors | 1 | 1997 | 102 | 0.010 |
Why?
|
|
Barnes's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|